ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.972,38
-1,41%
S&P 500
5.696,19
0,37%
Dow Jones
42.185,66
0,53%
Euro vs US Dollar
1,08456
-0,60%
Bitcoin
84.989,96
-2,19%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Acurx Pharmaceuticals Inc (ACXP)

  7. Acurx Pharmaceuticals Inc (ACXP) News

ACXP

Acurx Pharmaceuticals (ACXP)

Acurx Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ACXP
DatumZeitQuelleÜberschriftSymbolFirma
20/03/202505h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACXPAcurx Pharmaceuticals Inc
18/03/202512h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
18/03/202512h01PR Newswire (US)Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/03/202521h37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/03/202521h36Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/03/202521h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACXPAcurx Pharmaceuticals Inc
10/03/202521h30PR Newswire (US)Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingNASDAQ:ACXPAcurx Pharmaceuticals Inc
10/03/202512h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
10/03/202512h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ACXPAcurx Pharmaceuticals Inc
07/03/202514h00PR Newswire (US)Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct OfferingNASDAQ:ACXPAcurx Pharmaceuticals Inc
03/03/202514h00PR Newswire (US)Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI AntibioticsNASDAQ:ACXPAcurx Pharmaceuticals Inc
28/02/202514h00PR Newswire (US)Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
24/02/202514h00PR Newswire (US)Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDINASDAQ:ACXPAcurx Pharmaceuticals Inc
19/02/202514h00PR Newswire (US)JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC InhibitorsNASDAQ:ACXPAcurx Pharmaceuticals Inc
31/01/202522h11Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ACXPAcurx Pharmaceuticals Inc
08/01/202522h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACXPAcurx Pharmaceuticals Inc
08/01/202522h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACXPAcurx Pharmaceuticals Inc
07/01/202523h00PR Newswire (US)Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ACXPAcurx Pharmaceuticals Inc
07/01/202516h03Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ACXPAcurx Pharmaceuticals Inc
07/01/202516h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
06/01/202523h35PR Newswire (US)Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ACXPAcurx Pharmaceuticals Inc
06/01/202521h51Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ACXPAcurx Pharmaceuticals Inc
06/01/202514h30PR Newswire (US)Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)NASDAQ:ACXPAcurx Pharmaceuticals Inc
09/12/202414h00PR Newswire (US)Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA CommunicationsNASDAQ:ACXPAcurx Pharmaceuticals Inc
20/11/202413h01PR Newswire (US)Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNASDAQ:ACXPAcurx Pharmaceuticals Inc
20/11/202413h01PR Newswire (US)Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNASDAQ:ACXPAcurx Pharmaceuticals Inc
13/11/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
13/11/202413h00PR Newswire (US)Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
21/10/202413h00PR Newswire (US)Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/10/202414h00PR Newswire (US)Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor EngagementNASDAQ:ACXPAcurx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACXP

Kürzlich von Ihnen besucht

DBI
TDXP
Tec DAX
CCOM
US500
US 500
NASDAQ
GOOGL
Alphabet
USOTC
BASFY
BASF (QX)
COIN
ETHUSD
Ethereum
COIN
SOLUSD
Solana
NYSE
KO
Coca Cola
NASDAQ
MSFT
Microsoft
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
NKE
Nike
FX
EURGBP
Euro vs Sterling
TG
CBK
Commerzbank
TG
MBG
MercedesBenz
COIN
BTCUSD
Bitcoin
CCOM
SILVER
SILVER
DBI
MDAX
MDAX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten